Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Overall survival not reported · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | NR | No studies |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Progression free survival not reported · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR OS (at 3 years) · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.78 [0.62, 0.98] | 3 studies · 1421 participants | High |
Intervention NR TRM · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 0.31 [0.06, 1.51] | 2 studies · 177 participants | Low |
Intervention NR PFS (at 3 years) · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.64 [0.55, 0.74] | 3 studies · 1421 participants | Moderate |
Intervention NR TRM · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.19 [0.7, 2.01] | 3 studies · 1415 participants | Moderate |
Intervention NR SAEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.05 [0.89, 1.23] | 2 studies · 598 participants | Low |
Intervention NR Grade 3/4 AEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.15 [1.08, 1.23] | 3 studies · 1398 participants | Moderate |
Intervention NR OS not reported · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR PFS not reported · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Intervention NR Time to next treatment · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Intervention NR CRR · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.18 [0.93, 1.49] | 2 studies · 170 participants | Moderate |
Intervention NR All cause mortality ‐ 30 days · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.97 [0.8, 1.18] | 11 studies · 3319 participants | Low |
Intervention NR Bacteremia · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.96 [0.82, 1.12] | 7 studies · 1638 participants | Moderate |
Intervention NR Very wide CI · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Intervention NR Invasive fungal infection · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.4 [0.9, 2.19] | 4 studies · 929 participants | Low |
Intervention NR Episodes of febrile neutropenia · patients with prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.98 [0.94, 1.03] | 9 studies · 2140 participants | Moderate |
Intervention NR Adverse events requiring discontinuation of CSFs · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.33 [1, 1.76] | 4 studies · 770 participants | Very low |
Intervention NR All cause mortality ‐ End of · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.01 [0.98, 1.05] | 14 studies · 4029 participants | Low |
Intervention NR All cause mortality subgroup analysis age>60 · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.01 [0.97, 1.06] | 7 studies · 2035 participants | Low |
Intervention NR All‐cause mortality subgroup analysis age< 60 · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.08 [0.97, 1.2] | 5 studies · 1079 participants | Low |
Intervention NR All‐cause mortality ‐ sensitivity analysis · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.03 [0.99, 1.07] | 10 studies · 3405 participants | High |
Intervention NR Overall survival · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | HR 1 [0.93, 1.08] | 11 studies · 3335 participants | Low |
Intervention NR complete response · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.03 [0.99, 1.07] | 17 studies · 4774 participants | Moderate |
Intervention NR Disease free survival · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | OR 1 [0.9, 1.13] | 7 studies · 1639 participants | Low |
Intervention NR Relapse rate · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.97 [0.89, 1.05] | 10 studies · 2189 participants | Low |
Intervention NR Overall survival Median · patients with indolent B cell lymphoid malignancy Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 2 studies · 481 participants | Moderate |
Intervention NR All‐cause mortality Median · patients with indolent B cell lymphoid malignancy Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 4 studies · 1202 participants | Moderate |
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Mortality (median 3 years) · patients with primary CNS lymphoma Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane | HR 0.65 [0.38, 1.13] | 1 study · 79 participants | Moderate |
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Progression/relapse (median 3 years) · patients with primary CNS lymphoma Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane | HR 0.54 [0.31, 0.92] | 1 study · 79 participants | Moderate |
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Treatment‐related mortality · patients with primary CNS lymphoma Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane | RR 3.08 [0.33, 28.32] | 1 study · 79 participants | Moderate |
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Serious adverse events · patients with primary CNS lymphoma Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane | no estimate extracted | NR | No studies |
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Infections (grade 3 to 4) · patients with primary CNS lymphoma Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane | RR 9.23 [1.23, 69.47] | 1 study · 79 participants | Moderate |
Intervention NR Mortality (0 to 26 months) · Haemopoietic stem cell donors Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy… (2009) · Cochrane | RR 0.25 [0.05, 2.15] | 3 studies · 189 participants | Moderate |
Intervention NR Adverse events (day 7 to day 30 post‐donation) · Haemopoietic stem cell donors Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy… (2009) · Cochrane | no estimate extracted | 6 studies · 656 participants | Low |
Intervention NR Pain subsequent to donation ("after collection" ‐ day 30 post‐donation) · Haemopoietic stem cell donors Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy… (2009) · Cochrane | no estimate extracted | 6 studies · 656 participants | Low |
Intervention NR Psychological morbidity (immediately ‐ day 28 post‐donation) · Haemopoietic stem cell donors Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy… (2009) · Cochrane | no estimate extracted | 3 studies · 214 participants | Low |